AndroGel Dosing in Hepatic Impairment

What Is AndroGel and How Does It Work?

AndroGel delivers testosterone transdermally, raising serum testosterone into the physiologic male range (300 to 1,000 ng/dL) without the sharp peaks and troughs of intramuscular injections. Once absorbed through the stratum corneum, testosterone binds androgen receptors in target tissues, driving protein synthesis, libido, erythropoiesis, and bone mineral density. The gel is available as a 1% formulation (50 mg or 100 mg per packet or unit-dose tube) and a 1.62% formulation (20.25 mg, 40.5 mg, or 60.75 mg per actuation). FDA prescribing information confirms both strengths.

Transdermal vs. Oral Testosterone: Why the Route Matters for the Liver

Oral testosterone formulations undergo substantial first-pass hepatic metabolism, historically linking them to hepatocellular injury, peliosis hepatis, and cholestasis. A 2014 review in the NIH-affiliated literature summarized androgen-induced liver injury patterns across formulations. Transdermal gels sidestep the portal circulation entirely; absorbed testosterone enters the systemic venous system directly, producing a steadier plasma concentration and substantially lower peak hepatic exposure than any oral androgen.

Mechanism at the Receptor Level

Testosterone itself is the active ligand, but dihydrotestosterone (DHT) and estradiol are its most potent downstream signals. The enzyme 5-alpha-reductase converts testosterone to DHT in skin, prostate, and liver tissue, while aromatase converts it to estradiol. CYP19A1-mediated aromatization is well characterized in the NIH literature. In patients with cirrhosis, elevated aromatase activity and reduced hepatic testosterone clearance can shift this balance, raising estradiol relative to testosterone and compounding gynecomastia risk.

The T-Trials: Confirming Efficacy of Topical Testosterone

The Testosterone Trials (T-Trials), a coordinated set of seven double-blind, placebo-controlled trials in 790 men aged 65 and older with serum testosterone below 275 ng/dL, found that topical testosterone gel raised testosterone into the normal range in the majority of participants over 12 months. Snyder et al. (2016), NEJM, N=790, reported significant improvements in sexual function and bone mineral density with testosterone gel. The T-Trials did not enroll patients with significant hepatic impairment, leaving a specific evidence gap this article addresses.

FDA Labeling: What It Says About Hepatic Impairment

The FDA prescribing information for AndroGel 1% and AndroGel 1.62% states directly that testosterone pharmacokinetics in patients with hepatic impairment have not been studied. The full label is publicly available on FDA's accessdata portal. The label does not provide a specific dose reduction or titration schedule for Child-Pugh class A, B, or C patients. Prescribers are advised to use AndroGel with caution in men with liver disease.

What "Caution" Means in Practice

When FDA uses caution language without a dose table, the clinical implication is that the prescriber must individualize therapy using pharmacokinetic principles and serial serum testosterone measurements. No randomized controlled trial has specifically evaluated testosterone gel kinetics in compensated or decompensated cirrhosis. A 2020 review in the NIH literature examined androgen therapy in men with chronic liver disease and highlighted the absence of controlled trial data.

Child-Pugh Classification Relevance

Child-Pugh scoring stratifies hepatic reserve into class A (5 to 6 points, compensated), class B (7 to 9 points, significant functional compromise), and class C (10 to 15 points, decompensated). The Child-Pugh system is described in standard hepatology references indexed by NIH. In class A disease, hepatic drug-metabolizing capacity is often near-normal, and transdermal testosterone may behave similarly to its kinetics in healthy men. In class B and C disease, multiple variables converge to create unpredictable free-testosterone exposure.

Pharmacokinetics of Testosterone in Liver Disease

Hepatic impairment alters testosterone kinetics through at least four mechanisms that can interact and amplify each other. Understanding each helps the clinician predict direction-of-effect and choose a monitoring strategy.

SHBG Elevation and Free Testosterone

The liver synthesizes sex hormone-binding globulin (SHBG). Acute hepatic injury often reduces SHBG transiently, while chronic inflammation and cirrhosis characteristically raise SHBG. A foundational study in the NIH literature found SHBG elevation in cirrhotic men correlated with hypogonadal symptoms independent of total testosterone. Because only free testosterone (roughly 2 to 3% of total in healthy men) is biologically active, a high SHBG state can produce symptoms of hypogonadism even when total testosterone sits in the mid-normal range. Conversely, in early disease with reduced SHBG, a standard 50 mg dose might yield unexpectedly high free testosterone.

Reduced Hepatic Clearance

The liver catabolizes testosterone via CYP3A4 and conjugation pathways. Reduced CYP3A4 activity in cirrhosis can extend the half-life of testosterone derived from any route, including the slow steady-state absorption from a transdermal gel. CYP3A4 metabolism of steroid hormones is catalogued in the NIH drug-metabolism literature. Even though transdermal testosterone bypasses first-pass metabolism, reduced systemic clearance can accumulate active drug over the 24-hour dosing cycle, potentially pushing trough levels above the therapeutic ceiling.

Aromatase Upregulation

Hepatic aromatase (CYP19A1) converts testosterone to estradiol. In cirrhosis, peripheral and intrahepatic aromatase activity increases, and research indexed on PubMed demonstrates that estradiol-to-testosterone ratios rise substantially in cirrhotic men. The clinical consequences include gynecomastia, fluid retention, and suppression of the hypothalamic-pituitary-gonadal axis. Adding exogenous testosterone in this context may worsen gynecomastia rather than improve it, and dose titration should factor in estradiol measurement alongside total and free testosterone.

Protein Binding and Volume of Distribution

Albumin, synthesized exclusively in the liver, is the secondary binding protein for testosterone. In decompensated cirrhosis, albumin concentrations drop below 3.5 g/dL and can fall under 2.5 g/dL in severe disease. Lower albumin increases the unbound fraction of testosterone and of many co-administered drugs, raising effective free-drug exposure without any change in total testosterone on a standard assay. The relationship between albumin and sex-hormone availability is described in endocrine physiology literature on PubMed.

Practical Dosing Framework for Hepatic Impairment

No published dose-adjustment protocol from a randomized trial exists for AndroGel in hepatic disease. The framework below synthesizes FDA labeling, pharmacokinetic principles, and endocrinology society guidance into a risk-stratified clinical approach.

Child-Pugh Class A (Compensated Cirrhosis or Mild Hepatic Disease)

Start at the lowest approved dose: 20.25 mg per actuation (one pump) of AndroGel 1.62%, or 50 mg (one packet) of AndroGel 1%. Obtain a serum total testosterone and calculated free testosterone at 14 days, before the next daily application. Target total testosterone 400 to 700 ng/dL in most men, with free testosterone in the lower half of the reference range to reduce aromatization burden. Titrate conservatively, increasing by one actuation (1.62%) or one packet (1%) only after two consecutive trough values below 400 ng/dL. Check ALT, AST, alkaline phosphatase, and total bilirubin at baseline and every 3 months for the first year.

Child-Pugh Class B (Moderate Hepatic Impairment)

Use AndroGel only when the benefit-risk ratio is clearly favorable, for example, men with confirmed hypogonadism (total testosterone consistently below 300 ng/dL on two morning samples) and significant symptom burden. Start at 20.25 mg (one pump of 1.62%) and do not titrate upward for at least 30 days. Measure total testosterone, free testosterone, estradiol (by LC-MS/MS if available), SHBG, and albumin at 2 weeks and 4 weeks after initiation. Monitor for edema, gynecomastia, and hepatic encephalopathy. Endocrine Society guidelines on male hypogonadism recommend monitoring for edema in men with cardiac, renal, or hepatic disease.

Child-Pugh Class C (Decompensated Cirrhosis)

Testosterone replacement is generally not appropriate in decompensated cirrhosis. Multiple factors converge: unpredictable free-testosterone exposure from low albumin, high aromatase activity worsening gynecomastia, fluid retention worsened by the sodium-retaining properties of androgens, and the risk of precipitating or worsening hepatic encephalopathy. A hepatology position statement indexed on PubMed notes that androgens have been associated with hepatic decompensation in patients with underlying liver disease. If hypogonadism in a decompensated patient requires treatment, a hepatologist and endocrinologist should jointly manage the case before any androgen prescription is written.

Monitoring Parameters: Liver-Specific Additions to Standard TRT Surveillance

Standard testosterone replacement therapy monitoring includes serum testosterone at 3 and 6 months, hematocrit, PSA, and digital rectal exam per Endocrine Society guidelines. The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism specifies these intervals. Patients with pre-existing hepatic disease require a modified schedule.

Liver Function Tests

Obtain ALT, AST, alkaline phosphatase, GGT, and total bilirubin at baseline before starting AndroGel. Repeat at 6 weeks, 3 months, and then every 3 months through the first year. Discontinue or reduce the dose if ALT or AST rises above three times the upper limit of normal without another identifiable cause. A persistent rise in alkaline phosphatase or GGT in a patient with known hepatic disease warrants imaging and hepatology referral.

Estradiol Surveillance

Check serum estradiol by LC-MS/MS (not immunoassay, which overestimates in men) at each monitoring visit in hepatic impairment. Values above 40 pg/mL in a symptomatic man (gynecomastia, nipple sensitivity, edema) may justify dose reduction before considering aromatase inhibitor use, since aromatase inhibitors themselves are hepatically metabolized and carry their own hepatotoxicity signals. FDA-approved prescribing information for anastrozole notes hepatic metabolism via CYP3A4.

Hematocrit and Erythropoiesis

Testosterone stimulates erythropoiesis via EPO and direct bone marrow effects. In patients with cirrhosis and baseline anemia from portal hypertension and splenic sequestration, hematocrit responses may be blunted, making polycythemia less likely. Still, check hematocrit at 3 and 6 months; if it rises above 54%, hold the dose and recheck in 4 weeks. The Endocrine Society guideline recommends dose reduction or temporary discontinuation for hematocrit above 54%.

Secondary Exposure Risk and Application Site Guidance

The FDA's black box warning for AndroGel specifically addresses virilization in women and children from secondary exposure. This risk exists regardless of the patient's hepatic status. Application sites must be covered with clothing after the gel dries. FDA MedWatch safety communication on testosterone gel secondary exposure remains active. Patients with cirrhosis who have impaired coordination from hepatic encephalopathy may have difficulty applying gel consistently, which creates both under-dosing and exposure risk. Caregiver education is mandatory in this population.

Drug Interactions Relevant to Hepatic Impairment

Men with chronic liver disease often take multiple hepatically metabolized medications. Testosterone is a substrate of CYP3A4 and may interact with co-administered drugs that inhibit or induce this enzyme. The NIH drug interaction database summarizes CYP3A4 interactions with testosterone.

Anticoagulants

Testosterone potentiates warfarin's anticoagulant effect. A study indexed on PubMed demonstrated that testosterone reduces CYP2C9-mediated warfarin metabolism, raising INR by 30 to 50% in some patients. Patients with cirrhosis are often already coagulopathic and may be on anticoagulants for portal vein thrombosis. Check INR within 1 week of starting or adjusting AndroGel and recalibrate warfarin dosing accordingly.

Corticosteroids

Long-term corticosteroid use (for autoimmune hepatitis or alcohol-related hepatitis) can cause fluid retention independently. Combined use with testosterone may worsen edema and raise blood pressure. Monitor blood pressure and weight weekly for the first month in this combination.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity, which means glucose-lowering drug doses may need downward adjustment after successful TRT initiation in diabetic patients with hepatic disease. The interplay between testosterone, insulin resistance, and type 2 diabetes is reviewed in the endocrine literature on PubMed.

Alternatives to AndroGel When Hepatic Risk Is High

When a clinician judges that transdermal testosterone gel carries unacceptable hepatic risk, or when absorption is unreliable because of jaundice-related skin changes, the following alternatives exist. Each carries its own risk profile.

Testosterone Pellets (Testopel)

Subcutaneous pellet implants bypass both first-pass and transdermal variability, delivering steady serum testosterone over 3 to 6 months. No secondary-exposure risk exists. However, pellets cannot be titrated or withdrawn once implanted, and a patient who develops hepatic decompensation mid-cycle has no dose adjustment option. Pellet pharmacokinetics are described in clinical data indexed on PubMed.

Testosterone Injections (Testosterone Cypionate or Enanthate)

Intramuscular testosterone cypionate (100 to 200 mg every 1 to 2 weeks) or enanthate also bypasses hepatic first-pass metabolism. The sharp peak-to-trough variation may worsen aromatization at the peak, worsening gynecomastia. In patients with coagulopathy from cirrhosis, intramuscular injections carry bleeding risk; testosterone enanthate subcutaneous injection at lower volumes is sometimes used. Testosterone injection pharmacokinetics are detailed in FDA-approved labeling for Depo-Testosterone.

Nasal Testosterone (Natesto)

Natesto (testosterone 4.5 mg per actuation nasal gel, dosed three times daily) produces very low systemic exposure compared with transdermal gels, which might make it attractive in hepatic impairment. However, the 4.5 mg per dose and three-times-daily regimen result in peaks and troughs that some patients find burdensome, and the systemic testosterone levels achieved may be inadequate for men with severe hypogonadism. FDA prescribing information for Natesto is available through the accessdata portal.

Original Clinical Insight: Free Testosterone Is the Target in Hepatic Disease

Standard clinical practice focuses on total testosterone as the therapeutic target for TRT monitoring. In patients with hepatic impairment, where SHBG and albumin are both dysregulated, total testosterone can be frankly misleading. A man with Child-Pugh B cirrhosis, total testosterone of 520 ng/dL, and SHBG of 80 nmol/L may have a calculated free testosterone below 50 pg/mL, placing him in the hypogonadal free-testosterone range despite a "normal" total. Conversely, a man with early cirrhosis, reduced SHBG of 15 nmol/L, and total testosterone of 380 ng/dL may have a free testosterone above 150 pg/mL and be functionally eugonadal. Titrating AndroGel dose to free testosterone rather than total testosterone, calculated via the Vermeulen formula or measured by equilibrium dialysis, is a more reliable strategy in this population.

The Vermeulen formula for free testosterone calculation is validated in the endocrine literature indexed on PubMed.

Hypogonadism and Liver Disease: The Bidirectional Relationship

Hypogonadism is not merely incidental in liver disease. Approximately 70 to 90% of men with cirrhosis have low testosterone by standard criteria, compared with roughly 20% of men in the general population aged 40 to 79. A large epidemiologic study indexed on PubMed found that hypogonadism prevalence in cirrhotic men exceeded 70% regardless of etiology. The mechanisms include direct Leydig cell dysfunction from iron overload or alcohol toxicity, hypothalamic suppression from elevated estradiol, and reduced LH pulse amplitude from zinc deficiency common in cirrhosis.

Treating hypogonadism in cirrhotic men may improve quality of life, lean body mass, and bone mineral density, but no large randomized trial has demonstrated improved liver outcomes or reduced mortality with TRT in this population. A 2019 systematic review indexed on PubMed found insufficient evidence to recommend TRT routinely in men with cirrhosis and hypogonadism, citing the absence of adequately powered trials.

Application Technique and Absorption Considerations

AndroGel 1.62% is applied to the shoulder or upper arm. AndroGel 1% may be applied to the shoulder, upper arm, or abdomen. FDA labeling specifies these application sites to reduce secondary exposure. In patients with jaundice, xanthelasma, or spider angiomata (which can alter skin integrity), absorption may vary from published pharmacokinetic data. No controlled study has quantified this effect.

Patients should apply the gel after showering, to clean dry skin, and wait at least 5 minutes before dressing. The gel drying time is approximately 5 minutes; however, residual transfer remains possible for up to 2 hours, so contact precautions for partners and children apply for the full period. Bathing or swimming within 6 hours of application has been shown to reduce serum testosterone by approximately 13% in pharmacokinetic studies. Absorption and bathing-related pharmacokinetics are described in the AndroGel FDA label.